Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression: The SURE-PD3 Randomized Clinical Trial
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Importance: Urate elevation, despite associations with crystallopathic, cardiovascular, and metabolic disorders, has been pursued as a potential disease-modifying strategy for Parkinson disease (PD) based on convergent biological, epidemiological, and clinical data. Objective: To determine whether sustained urate-elevating treatment with the urate precursor inosine slows early PD progression. Design, Participants, and Setting: Randomized, double-blind, placebo-controlled, phase 3 trial of oral inosine treatment in early PD. A total of 587 individuals consented, and 298 with PD not yet requiring dopaminergic medication, striatal dopamine transporter deficiency, and serum urate below the population median concentration (<5.8 mg/dL) were randomized between August 2016 and December 2017 at 58 US sites, and were followed up through June 2019. Interventions: Inosine, dosed by blinded titration to increase serum urate concentrations to 7.1-8.0 mg/dL (n = 149) or matching placebo (n = 149) for up to 2 years. Main Outcomes and Measures: The primary outcome was rate of change in the Movement Disorder Society Unified Parkinson Disease Rating Scale (MDS-UPDRS; parts I-III) total score (range, 0-236; higher scores indicate greater disability; minimum clinically important difference of 6.3 points) prior to dopaminergic drug therapy initiation. Secondary outcomes included serum urate to measure target engagement, adverse events to measure safety, and 29 efficacy measures of disability, quality of life, cognition, mood, autonomic function, and striatal dopamine transporter binding as a biomarker of neuronal integrity. Results: Based on a prespecified interim futility analysis, the study closed early, with 273 (92%) of the randomized participants (49% women; mean age, 63 years) completing the study. Clinical progression rates were not significantly different between participants randomized to inosine (MDS-UPDRS score, 11.1 [95% CI, 9.7-12.6] points per year) and placebo (MDS-UPDRS score, 9.9 [95% CI, 8.4-11.3] points per year; difference, 1.26 [95% CI, -0.59 to 3.11] points per year; P = .18). Sustained elevation of serum urate by 2.03 mg/dL (from a baseline level of 4.6 mg/dL; 44% increase) occurred in the inosine group vs a 0.01-mg/dL change in serum urate in the placebo group (difference, 2.02 mg/dL [95% CI, 1.85-2.19 mg/dL]; P<.001). There were no significant differences for secondary efficacy outcomes including dopamine transporter binding loss. Participants randomized to inosine, compared with placebo, experienced fewer serious adverse events (7.4 vs 13.1 per 100 patient-years) but more kidney stones (7.0 vs 1.4 stones per 100 patient-years). Conclusions and Relevance: Among patients recently diagnosed as having PD, treatment with inosine, compared with placebo, did not result in a significant difference in the rate of clinical disease progression. The findings do not support the use of inosine as a treatment for early PD. Trial Registration: ClinicalTrials.gov Identifier: NCT02642393.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Ferric Reducing Ability of Plasma (FRAP) as a Measure of “Antioxidant Power”: The FRAP Assay
Benzie, I. F. F., & Strain, J. J. (1996) · Analytical Biochemistry · doi:10.1006/abio.1996.0292 · Cited by 22,951 · cited 1×
“g All data reported in this table are from the baseline assessment and were an unchanging characteristic except for the following: (1) Neuro-QoL depression score was assessed at screening visit 2; (2) DaT scan striatal specific binding ratio was assessed at the time of DaTscan or up to 6 months prior to screening visi…”
MethodTwo independent mutational events in the loss of urate oxidase during hominoid evolution
Wu, X., Muzny, D. M., Chi Lee, C., & Thomas Caskey, C. (1992) · Journal of Molecular Evolution · doi:10.1007/bf00163854 · Cited by 535 · cited 1×
“g All data reported in this table are from the baseline assessment and were an unchanging characteristic except for the following: (1) Neuro-QoL depression score was assessed at screening visit 2; (2) DaT scan striatal specific binding ratio was assessed at the time of DaTscan or up to 6 months prior to screening visi…”
Method(2006) · Annals of Neurology · doi:10.1002/(issn)1531-8249 · Cited by 513
Plasma Urate and Risk of Parkinson's Disease
Weisskopf, M., O'Reilly, E., Chen, H., Schwarzschild, M., & Ascherio, A. (2007) · American Journal of Epidemiology · doi:10.1093/aje/kwm127 · Cited by 390
Self-citationUrate as a Predictor of the Rate of Clinical Decline in Parkinson Disease
Ascherio, A. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.247 · Cited by 354
Self-citationSerum Urate as a Predictor of Clinical and Radiographic Progression in Parkinson Disease
Schwarzschild, M. A. (2008) · Archives of Neurology · doi:10.1001/archneur.2008.65.6.nct70003 · Cited by 310
Self-citationSerum uric acid levels and the risk of Parkinson disease
de Lau, L. M. L., Koudstaal, P. J., Hofman, A., & Breteler, M. M. B. (2005) · Annals of Neurology · doi:10.1002/ana.20663 · Cited by 301
Grinnon, S. T., Miller, K., Marler, J. R., Lu, Y., Stout, A., Odenkirchen, J., & Kunitz, S. (2012) · Clinical Trials · doi:10.1177/1740774512438980 · Cited by 280
Schwarzschild, M. A., Ascherio, A., Beal, M. F., Cudkowicz, M. E., Curhan, G. C., Hare, J. M., Hooper, D. C., Kieburtz, K. D., Macklin, E. A., Oakes, D., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2013.5528 · Cited by 243
Self-citationObservations on Serum Uric Acid Levels and the Risk of Idiopathic Parkinson's Disease
Davis, J. W., Grandinetti, A., Waslien, C. J., Ross, G. W., White, L. R., & Morens, D. M. (1996) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a008954 · Cited by 216
Determination of minimal clinically important change in early and advanced Parkinson's disease
Hauser, R. A., Auinger, P., & on behalf of the Parkinson Study Group (2011) · Movement Disorders · doi:10.1002/mds.23638 · Cited by 155
Self-citationTargeting urate to reduce oxidative stress in Parkinson disease
Crotty, G. F., Ascherio, A., & Schwarzschild, M. A. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2017.06.017 · Cited by 130 · cited 2×
“g All data reported in this table are from the baseline assessment and were an unchanging characteristic except for the following: (1) Neuro-QoL depression score was assessed at screening visit 2; (2) DaT scan striatal specific binding ratio was assessed at the time of DaTscan or up to 6 months prior to screening visi…”
BackgroundMethodSelf-citationDisrupted and transgenic urate oxidase alter urate and dopaminergic neurodegeneration
Chen, X. M., Burdett, T. C., Desjardins, C. A., Logan, R. A., Cipriani, S., Xu, Y., & Schwarzschild, M. A. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1217296110 · Cited by 123 · cited 2×
“Modified S&E ADL Scale score, mean (SD)c 94 (5) 94 (5)”
MethodSelf-citationBandres-Ciga, S., Saez-Atienzar, S., Kim, J. J., Makarious, M. B., Faghri, F., Diez-Fairen, M., Iwaki, H., Leonard, H., Botia, J., Ryten, M., et al. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02181-3 · Cited by 112
Guerreiro, S., Ponceau, A., Toulorge, D., Martin, E., Alvarez‐Fischer, D., Hirsch, É. C., & Michel, P. P. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06040.x · Cited by 101 · cited 1×
“g All data reported in this table are from the baseline assessment and were an unchanging characteristic except for the following: (1) Neuro-QoL depression score was assessed at screening visit 2; (2) DaT scan striatal specific binding ratio was assessed at the time of DaTscan or up to 6 months prior to screening visi…”
MethodBornavirus Encephalitis Shows a Characteristic Magnetic Resonance Phenotype in Humans
Finck, T., Liesche‐Starnecker, F., Probst, M., Bette, S., Ruf, V., Wendl, C., Dorn, F., Angstwurm, K., Schlegel, J., Zimmer, C., et al. (2020) · Annals of Neurology · doi:10.1002/ana.25873 · Cited by 95
Mendelian randomization of serum urate and parkinson disease progression
Simon, K. C., Eberly, S. W., Gao, X., Oakes, D., Tanner, C. M., Shoulson, I., Fahn, S., Schwarzschild, M. A., Ascherio, A., & on behalf of the Parkinson Study Group (2014) · Annals of Neurology · doi:10.1002/ana.24281 · Cited by 87
Self-citationMoccia, M., Picillo, M., Erro, R., Vitale, C., Longo, K., Amboni, M., Santangelo, G., Palladino, R., Capo, G., Orefice, G., et al. (2014) · European Journal of Neurology · doi:10.1111/ene.12533 · Cited by 63
Kia, D. A., Noyce, A. J., White, J., Speed, D., Nicolas, A., collaborators, I., Burgess, S., Lawlor, D. A., Smith, G. D., Singleton, A., et al. (2018) · Annals of Neurology · doi:10.1002/ana.25294 · Cited by 62
Plasma urate and risk of Parkinson's disease: A mendelian randomization study
Kobylecki, C. J., Nordestgaard, B. G., & Afzal, S. (2018) · Annals of Neurology · doi:10.1002/ana.25292 · Cited by 55
New hopes for disease modification in Parkinson's Disease
Poewe, W. H., Seppi, K., Marini, K., & Mahlknecht, P. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108085 · Cited by 55
Stephenson, D., Hill, D., Cedarbaum, J. M., Tome, M., Vamvakas, S., Romero, K., Conrado, D. J., Dexter, D. T., Seibyl, J., Jennings, D., et al. (2019) · Journal of Parkinson’s Disease · doi:10.3233/jpd-191648 · Cited by 46
Self-citationSleeman, I. J., Lawson, R. A., Yarnall, A. J., Duncan, G. W., Johnston, F., Khoo, T. K., & Burn, D. J. (2019) · Journal of Parkinson s Disease · doi:10.3233/jpd-181535 · Cited by 46 · cited 1×
“MDS-UPDRS (parts I-III) total score, mean (SD)d 32 (12) 34 (13)”
Oral I nosine P ersistently E levates P lasma antioxidant capacity in P arkinson's disease
Bhattacharyya, S., Bakshi, R., Logan, R. A., Ascherio, A., Macklin, E. A., & Schwarzschild, M. A. (2016) · Movement Disorders · doi:10.1002/mds.26483 · Cited by 45
Self-citationRomero, K., Conrado, D. J., Burton, J. K., Nicholas, T., Sinha, V. P., Macha, S., Ahamadi, M., Cedarbaum, J. M., Seibyl, J. P., MAREK, K. L., et al. (2019) · Clinical and Translational Science · doi:10.1111/cts.12619 · Cited by 19
Self-citationEffect of inosine on the plasma concentration of uridine and purine bases
Yamamoto, T., Moriwaki, Y., Cheng, J., Takahashi, S., Tsutsumi, Z., Ka, T., & Hada, T. (2002) · Metabolism · doi:10.1053/meta.2002.31322 · Cited by 18
Genome‐wide variant by serum urate interaction in Parkinson's disease
Nazeri, A., Roostaei, T., Sadaghiani, S., Chakravarty, M. M., Eberly, S. W., Lang, A. E., & Voineskos, A. N. (2015) · Annals of Neurology · doi:10.1002/ana.24504 · Cited by 15
Self-citationStephenson, D. T., Hill, D., Cedarbaum, J. M., Tome, M. B., Vamvakas, S., Romero, K., Conrado, D. J., Dexter, D. T., Seibyl, J. P., Jennings, D. L., et al. (2019) · Journal of Parkinson s Disease · doi:10.3233/jpd-199003 · Cited by 7
Self-citation
Cited by
Hyperuricemia and its related diseases: mechanisms and advances in therapy
Du, L., Zong, Y., Li, H., Wang, Q., Xie, L., Yang, B., Pang, Y., Zhang, C., Zhong, Z., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01916-y · Cited by 631
Mitochondrial dysfunction in Parkinson’s disease – a key disease hallmark with therapeutic potential
Henrich, M. T., Oertel, W. H., Surmeier, D. J., & Geibl, F. F. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00676-7 · Cited by 406
Brumm, M. C., Siderowf, A., Simuni, T., Burghardt, E., Choi, S. H., Caspell-Garcia, C., Chahine, L. M., Mollenhauer, B., Foroud, T., Galasko, D., et al. (2023) · Journal of Parkinson’s Disease · doi:10.3233/jpd-223433 · Cited by 70
Self-citationProgression subtypes in Parkinson’s disease identified by a data-driven multi cohort analysis
Hähnel, T., Raschka, T., Sapienza, S., Klucken, J., Glaab, E., Corvol, J.-C., Falkenburger, B. H., & Fröhlich, H. (2024) · npj Parkinson's Disease · doi:10.1038/s41531-024-00712-3 · Cited by 58
Metadata
- Authors
- The Parkinson Study Group SURE-PD3 Investigators, Bluett, B., Togasaki, D. M., Mihaila, D., Evatt, M., Rezak, M., Jain, S., Schwarzschild, M. A., Ascherio, A., Casaceli, C., Curhan, G. C., Fitzgerald, R., Kamp, C., Lungu, C., Macklin, E. A., Marek, K., Mozaffarian, D., Oakes, D., Rudolph, A., Shoulson, I., Videnovic, A., Scott, B., Gauger, L., Aldred, J., Bixby, M., Ciccarello, J., Gunzler, S. A., Henchcliffe, C., Brodsky, M., Keith, K., Hauser, R. A., Goetz, C., LeDoux, M. S., Hinson, V., Kumar, R., Espay, A. J., Jimenez-Shahed, J., Hunter, C., Christine, C., Daley, A., Leehey, M., de Marcaida, J. A., Friedman, J. H., Hung, A., Bwala, G., Litvan, I., Simon, D. K., Simuni, T., Poon, C., Schiess, M. C., Chou, K., Park, A., Bhatti, D., Peterson, C., Criswell, S. R., Rosenthal, L., Durphy, J., Shill, H. A., Mehta, S. H., Ahmed, A., Deik, A. F., Fang, J. Y., Stover, N., Zhang, L., Dewey, R. B., Gerald, A., Boyd, J. T., Houston, E., Suski, V., Mosovsky, S., Cloud, L., Shah, B. B., Saint-Hilaire, M., James, R., Zauber, S. E., Reich, S., Shprecher, D., Pahwa, R., Langhammer, A., LaFaver, K., LeWitt, P. A., Kaminski, P., Goudreau, J., Russell, D., Houghton, D. J., Laroche, A., Thomas, K., McGraw, M., Mari, Z., Serrano, C., Blindauer, K., Rabin, M., Kurlan, R., Morgan, J. C., Soileau, M., Ainslie, M., Bodis-Wollner, I., Schneider, R. B., Waters, C., Ratel, A. S., Beck, C. A., Bolger, P., Callahan, K. F., Crotty, G. F., Klements, D., Kostrzebski, M., McMahon, G. M., Pothier, L., Waikar, S. S., Lang, A., & Mestre, T.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2021-09-14
- Volume
- 326
- Issue
- 10
- Pages
- 926
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W3201157639
- Cited by
- 165
- References
- 28
- FWCI
- 10.92
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.